Preliminary Safety and Efficacy of BGB-11417, a Novel Bcl-2 Inhibitor, in **Combination With Azacitidine in Patients With Acute Myeloid Leukemia**

Jake Shortt,¹ Pau Montesinos,² Shuh Ying Tan,³ Teng Fong Ng,⁴ Chun Yew Fong,⁵ Paul Cannell,⁶ Kirsty Marshall,⁷ Sophie Leitch,⁸ Peter Tan,⁹ Sundra Ramanathan,¹⁰ Robin Gasiorowski,¹¹ Douglas Lenton,¹² Tse-Chieh Teh,¹³ José Antonio Pérez-Simón,¹⁴ Carolyn Grove,¹⁵ Xiaojun Huang,¹⁶ Courtney DiNardo,¹⁷ Katherine Naidu,¹⁸ Si Cheng,¹⁸ Yu Liu,¹⁸ Melannie Co,¹⁸ Wai Y. Chan,¹⁸ Haiyi Guo,¹⁸ and Andrew H. Wei¹⁹

¹Monash Health and Monash University, Clayton, Victoria, Australia; ²Hospital, Politecnico Universitario La Fe, Valencia, Spain; ³St Vincent's Hospital, Australia; ⁴Gold Coast University Hospital, Australia; ⁵Austin Health, Heidelberg, Victoria, Australia; ⁵Austin Health, Heidelberg, Victoria, Australia; ⁵Austin Health, Heidelberg, Victoria, Australia; ⁴Gold Coast University, Clayton, Victoria, Australia; ⁵Austin Health, Heidelberg, Victoria, Australia; ⁵Austin Health, Heidelberg, Victoria, Australia; ⁶Fiona Stanley Hospital, Australia; ⁸Fiona Stanley Hospital, Australia; ⁶Fiona Stanley Hospital, Australia; ⁹Fiona Stanley Hospital, Australia; ⁹One Clinical Research, Nedlands, Western Australia; ¹⁴Hospital, Australia; ¹⁴Hospital, Australia; ¹⁴Hospital, Concord Repatriation General Hospital, New South Wales, Australia; ¹⁴Hospital, Concord Repatriation, Victoria, Australia; ¹⁴Hospital, Prahran, Victoria, Australia; ¹⁴Hospital, New South Wales, Australia; ¹⁴Hospital, Concord Repatriation, Victoria, Australia; ¹⁴Hospital, Concord Repatriation, Victoria, Australia; ¹⁴Hospital, Concord Repatriation, Victoria, Australia; ¹⁴Hospital, Prahran, Prahran 18 Eigene USA; 18 Eigene USA; 18 Eigene (Shanghai) Co., Ltd., Shanghai, China; 16 Peking University People's Hospital, Nedlands, Western Australia; 16 Peking University of Texas MD Anderson Cancer Centre and Royal Melbourne, Victoria, Australia; 16 Peking University of Texas MD Anderson Cancer Centre and Royal Melbourne, Victoria, Australia and BeiGene USA; 18 Eigene (Shanghai) Co., Ltd., Shanghai, China; 17 University of Texas MD Anderson Cancer Centre and Royal Melbourne, Victoria, Australia; 16 Peking University People's Hospital, Beijing, China; 17 University of Texas MD Anderson Cancer Centre and Royal Melbourne, Victoria, Australia; 16 Peking University People's Hospital, Beijing, China; 17 University of Texas MD Anderson Cancer Centre, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Centre, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Centre, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Center, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Centre, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Centre, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Centre, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Centre, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Centre, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Centre, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Center, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Center, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Center, Houston, Texas, USA; and 19 Department of Clinical Haematology, Peter MacCallum Cancer Center, Houston, Texas, USA; and 19 Department of Clinical Haematolo

INTRODUCTION

- The efficacy of Bcl-2 inhibitors in combination with hypomethylating agents for treating newly diagnosed AML ineligible for intensive chemotherapy has been confirmed by phase 3 studies¹
- However, AML survival rates beyond 2 years are low¹ BGB-11417 is a potent and selective Bcl-2 inhibitor with the potential to achieve deeper target inhibition and responses in the clinical setting²
- In an AML xenograft model (human MOLM-13), BGB-11417 demonstrated a greater anti-tumor reduction than venetoclax at the same dose level, alone and when combined with azacitidine³
- Tolerable safety profile up to 640 mg as evaluated in a phase 1 dose-escalation study⁴
- Preliminary pharmacokinetic results showed dose-dependent increase in exposures⁵ Here, we present updated preliminary results of patients with AML enrolled in BGB-11417-103 (NCT04771130)


OBJECTIVES

- Primary objectives: Safety and tolerability, RP2D of BGB-11417 in AML when combined with azacitidine (parts 1 and 2), and efficacy (CR+CRh rate; part 3)
- Secondary objective: PK of BGB-11417
- **Exploratory objective:** Assess biomarkers and correlation with efficacy

METHODS

BGB-11417-103 is a phase 1b/2 dose-finding and expansion study of BGB-11417 in combination with azacitidine in patients with AML (TN unfit or R/R; **Figure 1**) and with MDS

Figure 1. Study Design



Safety monitoring committee reviews available patient safety and preliminary efficacy data to determine dose escalation in part 1, dose expansion to part 2, and the final RP2D to start part 3.

DLTs were assessed in cycle 1 (Figure 2)

- Patients were DLT evaluable if they received ≥80% the intended cumulative dose in cycle 1
- Response assessments based on European LeukemiaNet 2017 Response Criteria with assessment of hematologic improvement^{7,8} were performed every 3 cycles starting at the end of cycle 1
- For patients not in remission, an additional response assessment was performed at the end of cycle 2
- MRD status was assessed by multiparameter flow cytometry⁹ at the end of cycles 1 and 4, and at the end of cycle 2 if additional response assessment was performed

Figure 2. DLT Observation Window

Nonhematologic DLT Hematologic DLT **D28** D42

RESULTS

- As of the data cutoff of 5 September 2022, 57 patients with AML were enrolled and dosed (31 TN unfit and 26 R/R) in 4 dose cohorts (**Figure 3**)
- The median follow-up time was 5.3 months (range, 0.2-15.4) and the median treatment duration was 3.0 months (range, 0-15.4)

Figure 3. Patient Disposition

Enrolled (N=57) 40 mg x 10 d: n=16 80 mg x 10 d: n=17 160 mg x 10 d: n=16 160 mg x 28 d: n=8	Efficacy-evaluable population (n=57) Safety population/ all enrolled (n=57)			On active t (n=27;
		 Off treatment (n=30; 53%) AE (n=10)^a Disease progression/relapse (n=7) Proceed to transplant (n=6) Patient withdrawal (n=4)^b Investigator decision (n=2)^c 	→	Contin posttrea follow
Data cutoff: September	5 2022	• Start of new anticancer therapy (n=1) ^d		(n=11;

Data cuton. September 5, 2022

^aAE leading to discontinuation of both study drugs: bacterial sepsis, pulmonary sepsis, neutropenic sepsis, bronchopulmonary aspergillosis, pneumonia, sepsis, septic shock, anemia, thrombocytopenia, metastatic squamous cell carcinoma, aortobronchial fistula. Patient withdrawal: unable to adhere to study visits (n=2), requested no further treatment of AML/palliative care (n=2). cInvestigator decision: no appreciable response after 2 cycles, switched to chemotherapy (n=1), patient was nonadherent (n=1). dWithout disease progression.

RESULTS (CONTINUED)

Table 1. Baseline Characteristics

Characteristics, n (%)	TN (n=31)	R/R (n=26)
Median age (range), years	77 (64-91)	64 (29-80)
Male	19 (61)	16 (62)
AML type		
De novo	26 (84)	23 (88)
AML risk stratifications ^a		
Intermediate	11 (35)	8 (31)
Adverse	11 (35)	13 (50)
Bone marrow blast count		
≥30 to <50%	11 (35)	3 (12)
≥50%	12 (39)	11 (42)
Most common genetic abnormalities		
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); <i>CBFB-MYH11</i>	3 (10)	7 (27)
NPM1	4 (13)	5 (19)
-7 or del(7q)	5 (16)	3 (12)
Complex karyotype or monosomal karyotype	5 (16)	3 (12)
-5 or del(5q)	5 (16)	2 (8)
IDH1	2 (6)	5 (19)
RUNX1	2 (6)	4 (15)
FLT3 ^b	4 (13)	2 (8)
IDH2 ^c	1 (3)	5 (19)
<i>TP53</i> aneuploidy	4 (13)	1 (4)
t(8;21)(q22;q22.1); RUNX1-RUNX1T1	3 (10)	1 (4)

^aBased on ELN 2017 risk stratifications by genetics. ^bFLT3-ITD (low or high allelic ratio), none FLT3-TKD. ^cIncludes R140 and R172 mutations.

• Most patients had 3 cycles of treatment. Patients in the 80 mg x 10 days cohort had the longest duration of treatment (median of 7 cycles, **Table 2**)

Table 2. Treatment Exposure in AML

	40 mg x 10 d		80 mg x 10 d		160 mg x 10 d		160 mg x 28 d	
	(n=16)		(n=17)		(n=16)		(n=8)	
	BGB-11417	Aza	BGB-11417	Aza	BGB-11417	Aza	BGB-11417	Aza
Median duration of treatment (min, max), mo	3.3	3.3	7.8	7.8	3.1	3.1	2.2	1.6
	(0.3, 10.6)	(0.2, 10.6)	(0.3, 15.4)	(0.2, 15.4)	(0.1, 9.9)	(0.1, 9.7)	(0, 4.1)	(0.1, 3.7)
Median cycle duration ^a (min, max), d	32		33		34		38	
	(13, 44.5)		(8, 40.6)		(5, 40.0)		(2, 51.7)	
Median no. of cycles	3		7		3		2	
(min, max)	(1, 11)		(1, 14)		(1, 10)		(1, 4)	

*Each cycle duration should be 28 days. It initiation of the following cycle is delayed for any reason, the cycle duration will be measured up to the last day before the next cycle was initiated or treatment discontinuation, whichever occurred first

Safety

Table 3. Summary of TEAEs

TEAEs, n (%)	Total (N=57)	
Any TEAE	57 (100)	Six patients had
Grade ≥3	53 (93)	(n=5; 4 TN, 1 R/R)
Serious	46 (81)	Table 3)
Leading to death	6 (11)	 Pulmonary ser
Death within 30 days of first dose	1 (2)	COPD); hospit
Death within 60 days of first dose	3 (5)	
Leading to discontinuation		patient with ba
BGB-11417	10 (18)	aspergillosis (8
Azacitidine	11 (19)	progression), r
Leading to reduction		a patient with
BGB-11417	6 (11)	AML); sepsis (1
Azacitidine	9 (16)	progression), a
Leading to cycle delays		1 0 /
BGB-11417	37 (65)	complication o
Azacitidine	37 (65)	

• Neutropenia, thrombocytopenia and febrile neutropenia were the most common reasons for cycle delays. The median cycle duration was 33 days (**Table 2**)

- DLT (grade 4 neutropenia and thrombocytopenia lasting beyond day 42) occurred in 2 patients in the 80 mg x 10 days cohort. No new DLTs were observed with higher doses (**Table 4**)

- No clinical TLS was observed. Laboratory TLS occurred in a patient treated with 160 mg x 10 days (assessed based on Howard criteria⁶). This patient had pre-existing history of chronic kidney disease. He was managed successfully as an outpatient and fully recovered after 4 days

Table 4. DLTs and TLS


	BGB-11417						
DLT evaluableª, n (%)	40 mg x 10 d (n=14)	80 mg x 10 d (n=15)	160 mg x 10 d (n=15)	160 mg x 28 d (n=6)	Total (n=50)		
DLT	0	2 (13)	0	0	2 (4)		
Hematologic	0	2 (13)	0	0	2 (4)		
Grade 4 neutropenia	0	1 (7)	0	0	1 (2)		
Grade 4 thrombocytopenia	0	2 (13)	0	0	2 (4)		
Nonhematologic (grade ≥3)	0	0	0	0	0		

Part 3



Safety (cont.)

• The most common TEAEs were neutropenia, thrombocytopenia and anemia, and the most common non-hematologic TEAEs



Efficacy


^aCRh was defined by Bloomfield et al.⁷

- CR+CRh was achieved in 65% of TN and 50% of R/R patients (Table 5)
- Most CR+CRh in TN AML (15 of 20) was achieved by the end of cycle 1
- The 80 mg x 10 day cohort (n=17) had the longest treatment duration with a median of 7 cycles (**Figure 5**) - CR+CRh was seen in 73% and 67% of TN and R/R patients, respectively - CR was seen in 73% and 50% of TN and R/R patients, respectively
- Reduction in bone marrow blast is shown in Figure 6
- Twenty-seven patients met CR+CRh with evaluable flow cytometry MRD results, and 13 (48%) of the 27 achieved MRD negativity (malignant AML <0.1% per ELN 2018⁹)

Table 5. Summary of Complete Responses

	40 mg x 10 d		80 mg x 10 d		160 mg x 10 d		160 mg x 28 d		Total	
Response	TN (n=9)	R/R (n=7)	TN (n=11)	R/R (n=6)	TN (n=8)	R/R (n=8)	TN (n=3)	R/R (n=5)	TN (n=31)	R/R (n=26)
CR+CRh ,ª n (%)	5 (56)	4 (57)	8 (73)	4 (67)	6 (75)	3 (38)	1 (33)	2 (40)	20 (65)	13 (50)
CR+CRh after 1 cycle	4 (44)	1 (14)	5 (45)	1 (17)	5 (63)	1 (13)	1 (33)	2 (40)	15 (48)	5 (19)
CR+CRi , n (%)	5 (56)	3 (43)	8 (73)	4 (67)	6 (75)	3 (38)	1 (33)	2 (40)	20 (65)	12 (46)
CR	4 (44)	2 (29)	8 (73)	3 (50)	3 (38)	1 (13)	1 (33)	1 (20)	16 (52)	7 (27)
Median time to CR, mo	1.3	3.2	1.8	3.8	1.2	1.9	1.2	1.1	1.3	3.8
Median BGB-11417 treatment	4.9	1.7	7.8	7.3	3.3	2.3	1.4	2.3	3.7	2.6
duration (range), mo	(0.3-10.6)	(1.3-6.2)	(0.3-15.2)	(0.4-15.4)	(0.3-9.9)	(0.1-9.7)	(0.0-2.7)	(0.9-4.1)	(0.0-15.2)	(0.1-15.4)

Response assessments based on 2017 ELN response criteria with assessment of hematologic improvement (part 3).^{7,8} Number of patients who did not have a posttreatment response assessment: in TN 40 mg and 80 mg (n=1 each), in TN 160 mg x 10 days and x 28 days (n=2 each), and in R/R 160 mg x 10 days (n=1).



All (N=57)

71 (29-91)

49 (86)

19 (33)

24 (42)

14 (25)

23 (40)

10 (18)

9 (16)

8 (14)

8 (14)

7 (12)

7 (12)

6 (11)

6 (11)

6 (11)

5 (9)

4 (7)

Total

3.0

(N=57)

(0, 15.4) (0.1, 15.4)


(2, 51.7)


(1, 14)

Aza BGB-11417 Aza

3.0

epsis (40 mg x 10 d; in a patient with bital-acquired pneumonia (80 mg x 10 d; in a paseline neutropenia); bronchopulmonary (80 mg x 10 d; occurred following disease neutropenic sepsis (160 mg x 10 d; in n type II diabetes, related to underlying (160 mg x 10 d; occurred following disease , and aortobronchial fistula (160 mg x 28 d; of a thoracic aneurysm)





CONCLUSIONS

- BGB-11417 (40, 80, 160 mg) plus azacitidine was generally well tolerated in patients with AML
- DLTs (grade 4 neutropenia/thrombocytopenia) only occurred in the 80 mg cohort; no new DLTs occurred with further dose escalation
- Neutropenia (65%) was the most common grade \geq 3 TEAE, manageable with dose modifications and supportive care
- No dose-dependent toxicities were observed
- Maximum tolerated dose was not reached
- The combination was effective in both TN and R/R settings at the four dose levels tested
- CR/CRh was achieved in 65% TN and 50% R/R patients
- Efficacy analysis of molecular subgroups, safety expansion, and evaluation of higher doses of BGB-11417 are ongoing; inclusion of patients with AML who failed hypomethylating agents is also planned

REFERENCES

- DiNardo et al. N Engl J Med 2020;383(7):617-62 2. Hu et al. Cancer Res 2020;80(suppl 16):3077
- 3. Data on file. BGB-11417 Investigator Brochure 4. Opat et al. EHA 2022. Abstract P687
- 5. Shortt et al, EHA 2022. Abstract P590 6. Howard SC, et al. N Engl J Med 2011;364(19):1844-1854. Erratum in: N Engl J Med 2018;379(11):1094
- 7. Bloomfield CD, et al. *Blood Rev* 2018:32(5):416-425 8. Döhner H, et al. *Blood* 2017;129(4):424-447 9. Schuurhuis GJ, et al. Blood 2018;131(12):1275-129

ABBREVIATIONS

AE, adverse event; AML, acute myeloid leukemia; aza, azacitidine; BCL2, B-cell lymphoma 2; COPD, chronic obstructive pulmonary disease; CR, complete response; CRh, complete response with partial hematologic recovery; CRi, CR with incomplete hematologic recovery; CYP3A4, cytochrome P450 3A4; D, day; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; ELN, European LeukemiaNet; ITD, internal tandem duplication; IV, intravenous; MLFS, morphological leukemiafree state; MDS, myelodysplastic syndrome; MRD, minimal residual disease; PD, progressive disease; PI principal investigator; PK, pharmacokinetics; RP2D, recommended phase 2 dose; R/R, relapsed/refractory; SC, subcutaneous; SD, stable disease; TEAE, treatment-emergent adverse event; TKD, tyrosine kinase domain; TLS, tumor lysis syndrome; TN, treatment naïve.

DISCLOSURES

JS: consulting for Otsuka, Astellas, Novartis, Mundipharma, BMS; research funding from Amgen, Astellas, BioCurate; speakers bureau for Mundipharma PM: consulting role with Menarini/Stemline, Otsuka, AbbVie, BMS, Novartis, Jazz, BeiGene, Astellas, Pfizer, Incyte, Takeda, Ryvu, Nerviano; research funding from Menarini/Stemline, AbbVie, BMS, Novartis, Jazz, Pfizer, Takeda; speakers bureau for AbbVie, BMS, Jazz, Astellas, Pfizer

TFN: research funding from Spinnaker-Health Research Foundation and WA Health CYF: consulting for AbbVie, Astellas, BeiGene, BMS, Pfizer, Jazz, Otsuka, Amgen, Novartis; research funding from Astellas; honoraria from AbbVie, Astellas, BeiGene, BMS, Pfizer, Jazz, Otsuka, Amgen, Novartis; speakers bureau for AbbVie, Pfizer KM: honoraria from AbbVie RG: honoraria from AbbVie, Astellas, Janssen, MSD, Novartis, Otsuka, Takeda

PT: research funding from Novartis, Celgene, Janssen, and EpimAb JAPS: consulting and advisory role for Novartis, Jansen, Gilead, Jazz, Takeda, Alexion; research funding from Takeda, AbbVie, Pfizer; honoraria and travel expenses from Novartis, Jansen, Gilead, Jazz, Takeda, Alexion

CG: advisory board for AbbVie, Astellas, Otsuka XH: consulting for Astellas, Takeda, Janssen, Pfizer, MSD, Sanofi, BeiGene; research funding from BeiGene, Sanofi, Astellas; honoraria from Astellas, Takeda, Janssen, Pfizer, MSD, Sanofi, BeiGene; travel expenses from BeiGene CD: honoraria from AbbVie, Agios, Genentech, Servier, BMS, Celgene, Novartis, Takeda, Jazz; consulting for BMS, Celgene, Servier, Kura, GSK, Genmab; research funding from AbbVie, Agios, Servier, BMS, Foghorn, Immune-Onc, Eli Lilly KN, JP, SC, YL, MC, HG: employment and stock ownership with BeiGene

WYC: employment and stock with BeiGene; stock with BMS AHW: consulting for Servier, BeiGene, AbbVie, Novartis; research funding from Novartis, AbbVie, Servier, Janssen, BMS, Syndax, Astex, AstraZeneca, Amgen; honoraria from Novartis, AstraZeneca, Astellas, Janssen, Amgen, Roche, Pfizer, AbbVie, Servier, Gilead, BMS, Shoreline, MacroGenics, Agios; speakers bureau for AbbVie, Novartis, Servier, BMS, Astellas; travel expenses from Novartis, Servier: patent with Servier SYT, PC, SL, SR, DL, TCT: nothing to disclose

CORRESPONDENCE

Jake Shortt, MD, PhD Monash Health and Monash University Clayton, Victoria, Australia jake.shortt@monashhealth.ord

ACKNOWLEDGMENTS

We would like to thank the investigators, site support staff, and especially the patients for participating in this study. This study was sponsored by BeiGene. Editorial support was provided by Bio Connections LLC and funded by BeiGene.

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASH[®] and the authors of this poster.



Presented at the American Society of Hematology Annual Meeting, December 10–13, 2022, New Orleans, Louisiana, USA